IDEAYA Biosciences Appoints Darrin Beaupre As Chief Medical Officer

RTTNews | Pred 1026 dňami
IDEAYA Biosciences Appoints Darrin Beaupre As Chief Medical Officer

(RTTNews) - Oncology company IDEAYA Biosciences, Inc. (IDYA) announced that Darrin Beaupre has joined the company as its Chief Medical Officer, effective November 21, 2022.

Beaupre's extensive career includes various clinical development and translational research roles in industry, including most recently at BioSplice Therapeutics as Chief Medical Officer and Head of Research and Development in Oncology.

Beaupre previously served as Senior Vice President, Head of Early Oncology Development and Clinical Research at Pfizer, Inc., where he led cross-disciplinary groups including clinical development, clinical pharmacology, translational oncology and clinical operations related study clinicians.

Beaupre also served at Pharmacyclics (Abbvie) as Vice President, Head of Early Development and Immunotherapy, and at Amgen as Medical Director.

He was previously an Assistant Professor at the H. Lee Moffitt Cancer Center and Research Institute, and also held various earlier appointments at the University of Miami and the M.D. Anderson Cancer Center.

read more
IDEAYA Biosciences Q4 Results Misses Estimates

IDEAYA Biosciences Q4 Results Misses Estimates

IDEAYA Biosciences, Inc. (IDYA), a precision medicine oncology company, announced net loss of $32.64 million or $0.52 per share, wider than $23.07 million or $0.50 per share in the prior-year quarter.
RTTNews | Pred 577 dňami
IDEAYA Biosciences Says FDA Clears IND For Pol Theta Helicase Development Candidate GSK101

IDEAYA Biosciences Says FDA Clears IND For Pol Theta Helicase Development Candidate GSK101

Oncology company IDEAYA Biosciences, Inc. (IDYA) announced Monday the clearance of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for initiation of a GSK-sponsored Phase 1/2 clinical trial to evaluate GSK101 (IDE705) for the treatment of patients having tumors with BRCA or other homologous recombination (HR) mutations or homologous recombination deficiency (HRD).
RTTNews | Pred 760 dňami
Bank Of Japan Holds Rate Steady; Plans To Lower ETF Holdings

Bank Of Japan Holds Rate Steady; Plans To Lower ETF Holdings

The Japanese central bank left its key interest rate unchanged on Friday, as expected, but surprised markets with a decision to reduce the holdings of its massive stock of exchange-traded funds, suggesting that the monetary policy normalization is underway. The Bank of Japan policy board, led by Governor Kazuo Ueda, voted 7-2 to hold the uncollateralized overnight call rate at around 0.5 percen
RTTNews | Pred 1 h 15 min
Bay Street Likely To Open On Subdued Note

Bay Street Likely To Open On Subdued Note

Canadian shares may open on a somewhat subdued note on Friday with investors reacting to retail sales data, and looking to take some profits following recent gains.
RTTNews | Pred 1 h 59 min
Pound Slides As UK Bond Yield Soars

Pound Slides As UK Bond Yield Soars

The British pound weakened against other major currencies in the European session on Friday, as long-dated UK bond yields rise sharply in response to increasing public sector borrowings in August.
RTTNews | Pred 3 h 44 min
Sensex, Nifty End Lower On Profit Taking

Sensex, Nifty End Lower On Profit Taking

Indian shares ended lower on Friday, with key benchmark indexes Sensex and Nifty snapping a three-day winning streak that was supported by GST reforms, encouraging progress in India-U.S. trade discussions and the Federal Reserve's first rate cut of the year.
RTTNews | Pred 4 h 3 min